The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Tips for Designing Studies That Actually Reveal Causal Inference

Tips for Designing Studies That Actually Reveal Causal Inference

May 13, 2021 • By Ruth Jessen Hickman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In a randomized, controlled trial, the risk difference between groups is interpreted as a causal effect of the treatment, according to Seoyoung C. Kim, MD, ScD, MSCE, an associate professor of medicine in the Division of Pharmacoepidemiology and Pharmacoeconomics and the Division of Rheumatology, Inflammation and Immunity at Brigham and Women’s Hospital and Harvard Medical School, and an instructor in epidemiology at the Harvard T.H. Chan School of Public Health, Boston.

You Might Also Like
  • Shortcomings and Promises of Genome-wide Association Studies
  • Studies Suggest Similar Risks for Biologics vs. Conventional Therapies for Rheumatoid Arthritis
  • Can REVEAL Tool Predict Survival in SSc-Related Pulmonary Arterial Hypertension?
Explore This Issue
May 2021
Also By This Author
  • Study Explores Palindromic Rheumatism to Predict RA Development

But when a randomized, controlled trial can’t be conducted, well-designed and well-executed observational analyses can be useful for causal inference. Dr. Kim says estimation of causal effects in such studies is challenging, but doable with careful methodological consideration.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Kim presented this and other information on the key concepts of causal inference and mediation analysis in a virtual course sponsored by the VERITY grant (Value and Evidence in Rheumatology Using Bioinformatics and Advanced Analytics) on March 4. Through this and other offerings, VERITY is helping promote highly rigorous research in clinical topics in rheumatology.

Causal Inference

In her presentation, Dr. Kim focused on topics related to causal inference, the process of determining the independent, actual effects of a component within a system. These can be visualized with the help of directed acyclic graphs, which can be used as tools to think through the possible causal ways a variety of factors might interact.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Kim discussed multiple common mistakes researchers make in constructing their studies and repeatedly emphasized the importance of correct initial study design. Various statistical methods, where appropriate, are also important to help minimize confounding, such as multivariable adjustment, stratification, propensity score methods, etc. However, Dr. Kim added, “Even if you have all kinds of fancy statistical methods, if your design is wrong, it will not save your study.”

Although several different kinds of observational studies are available to researchers, Dr. Kim emphasized that to infer a causal effect, the treatment exposure must occur prior to assessed outcomes. Thus, cross-sectional, case series or case control studies are not well suited to causal inference.

Dr. Kim made an important distinction between common causes in a network of events (e.g., confounders) and common effects (i.e., colliders in the language of causal inference). Confounders are variables that causally influence both the original event and the outcome being studied, whereas colliders are factors that may be causally influenced by both the original event and the studied outcome.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Although it is critical to make statistical adjustments for common causes to remove confounding, adjusting for common effects will introduce selection bias into the results. “The difficult part is that it is not always clear which is a confounder [and which is a collider] unless you set your timeline correctly,” she explained. “Also, you need to have expert knowledge to determine these factors. Not all statistical methods can tell you which is a confounder and which is a collider.”

Dr. Kim also warned against a common study design in which nonusers of a treatment are compared with prevalent users (e.g., current users or ever users). In other words, patients using a drug of interest are compared to those not taking any treatment at all. But in clinical practice, there may be important confounding reasons why a patient might not be prescribed a treatment, such as increased frailty or less severe symptoms.

“If you happen to have a similar drug to use as a reference to the drug of interest, that is, an active comparator design, the unmeasured confounder will be much less,” Dr. Kim explained.

Pages: 1 2 3 4 | Single Page

Filed Under: Research Reviews Tagged With: Cause, study design, trialsIssue: May 2021

You Might Also Like:
  • Shortcomings and Promises of Genome-wide Association Studies
  • Studies Suggest Similar Risks for Biologics vs. Conventional Therapies for Rheumatoid Arthritis
  • Can REVEAL Tool Predict Survival in SSc-Related Pulmonary Arterial Hypertension?
  • eConsult Communications Reveal the Common Questions from Primary Care Physicians about Rheumatology Care

About Ruth Jessen Hickman, MD

Ruth Jessen Hickman, MD, was born and raised in eastern Kentucky, where she first cultivated her love of literature, writing and personal narratives. She attended Kenyon college, where she received a Bachelor of Arts in philosophy, summa cum laude. She worked with individuals with psychiatric conditions and later in a neuroscience lab at the University of Illinois, Chicago, before graduating from Indiana University Medical School in 2011. Instead of pursuing clinical medicine, Ruth opted to build on her strength of clearly explaining medical topics though a career as a freelance medical writer, writing both for lay people and for health professionals. She writes across the biomedical sciences, but holds strong interests in rheumatology, neurology, autoimmune diseases, genetics, and the intersection of broader social, cultural and emotional contexts with biomedical topics. Ruth now lives in Bloomington, Ind., with her husband, son and cat. She can be contacted via her website at ruthjessenhickman.com.

View more by this author»

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)